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doi:10.1016/j.jmii.2011.12.021There are few reports of invasive infections caused by Brevundimonas vesicularis. We report
two cases of B. vesicularis bacteremia confirmed by culture and 16S rRNA sequence analysis
with highly variable sensitivity to broad-spectrum antibiotics. Initial empiric therapy
with anti-pseudomonal antibiotics plus trimethoprim-sulfamethoxazole for hospital-acquired
B. vesicularis infections should be considered.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Brevundimonas vesicularis (previously known as Coryne-
bacterium vesiculare and Pseudomonas vesicularis) is
classified as a group IV member of the genus Pseudo-
monas.1,2 Segers et al2 re-classified P. diminuta and P.of Infectious Diseases and
ternal Medicine, Tri-Service
edical Center, Number 325,
4, Taipei, Taiwan.
u.tw (J.-C. Lin).
an Society of Microbiology. Publvesicularis into a new genus (Brevundimonas) in 1994.
Isolated from both environmental and clinical specimens,2,3
B. vesicularis is an aerobic, nonsporulating and glucose
non-fermenting Gram-negative bacillus (GNB) with distinct
nutritional requirements and biochemical characteris-
tics.4,5 The organism produces slow-growing and yellow-
pigmented colonies on blood and chocolate agar.4e7
Although some authors have observed that the organism
does not grow in MacConkey’s agar,4 longer incubation
might reveal macroscopically-visible growth.6 Few reports
of invasive infections caused by B. vesicularis exist in the
literature. Herein we report on two patients with
B. vesicularis bacteremia and review the previously re-
ported cases.ished by Elsevier Taiwan LLC. All rights reserved.
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Case 1
An 83-year-old man with type 2 diabetes, poor glycemic
control for 20 years and hypertension for 2 years underwent
coronary artery bypass grafting for severe stenosis. Twelve
days post-operatively, he developed a high fever and chills
associated with progressive leukocytosis. Two sets of blood
cultures showed a GNB. Empiric parenteral administration
of ceftazidime was initiated. A 16S rRNA sequence analysis
was used to confirm the isolates. The bacterium was then
identified as B. vesicularis. The organism was susceptible
to cefazolin, amikacin, gentamicin, ampicillin/sulbactam,
piperacillin/tazobactam, ceftazidime, ceftriaxone, imipe-
nem, cefepime and ertapenem, and was resistant to
ampicillin and ciprofloxacin. Two weeks after treatment,
the blood cultures were negative and the patient was dis-
charged home without complications.
Case 2
A 25-year-old man had anaplastic large T-cell lymphoma
for 2 years. Febrile neutropenia developed 1 day after he
underwent autologous peripheral blood stem-cell trans-
plantation. Empiric parenteral administration of cefepime
plus vancomycin was used. A GNB isolated from the blood
was identified as B. vesicularis, which was confirmed by 16S
rRNA sequence analysis 5 days later. The organism was
susceptible to cefazolin, amikacin, gentamicin, ampicillin/
sulbactam, piperacillin/tazobactam, ceftriaxone, imipe-
nem and ertapenem, and was resistant to ampicillin, cef-
tazidime, cefepime and ciprofloxacin. Removal of the
Hickmann catheter was followed by intravenous ceftriax-
one therapy for 10 days. The subsequent blood cultures
were negative and the patient was discharged home
without complications 21 days after transplantation.
Analysis
The blood cultures of the presented cases were performed
using the BacT/ALERT Microbial Detection System (bio-
Me`rieux SA, Marcy l’E´toile, France). For identification and
susceptibility testing using standard methods, the organism
from the blood culture bottle was inoculated onto
MacConkey’s and chocolate agar plates. The identification
and susceptibility testing for the isolates in our cases via
the biochemical characteristics were tested by Vitek 2
(bioMe´rieux, Inc., Durham, NC, USA) ID-GNB (identification
of GNB) and antimicrobial susceptibility testing (alanine
tminotransferase)-GN04 cards in our laboratory using the
automatic Vitek 2 system based on specific characteristics,
as reported previously.3
Discussion
There are few reports in the literature on invasive infec-
tions caused by B. vesicularis. We conducted a PubMed
literature search limited to English-language publications
using Pseudomonas vesicularis, Brevundimonas vesicularisand Corynebacterium vesiculare as search terms, and 14
cases were found. The demographic data and clinical
characteristics of patients with B. vesicularis infections are
listed in Table 1.4e16 Infections included bacteremia (10
cases), cutaneous infections (two cases), meningitis (one
case), peritonitis (one case) and septic arthritis (one case).
These patients were immunocompromised because of end-
stage renal disease,10,11,14 systemic lupus erythematosus
involving prolonged steroid use,4 sickle cell anemia,5
hematological malignancy8 and neutropenia. The inci-
dence of bloodstream infections of B. vesicularis in immu-
nocompromised as well as immunocompetent patients is
increasing (Table 1). The factors predisposing patients to
this infection remain unknown. Good outcomes were noted
after removal of catheters in prior cases12,14 and in one of
the present cases.
Table 2 summarizes the antibiotic susceptibility and
resistance of this pathogen in the previously reported and
present cases. The in vitro antibiotic susceptibility of
B. vesicularis is highly variable. In previously reported
cases4,16 and the present two cases of hospital-acquired
bacteremia, B. vesicularis was resistant to ampicillin and
ciprofloxacin, and in one case to ceftazidime and cefepime.
Mondell12 described a case of hospital-acquired meningitis
with susceptibility to ciprofloxacin, but not to any other
anti-pseudomonal antibiotics. In isolates susceptible to
aminopenicillins, anti-pseudomonal penicillins, cephalo-
sporins, carbapenems and aminoglycosides,5,13e15 resis-
tance to aztreonam, ceftazidime and ciprofloxacin was
higher in hospital- than community-acquired organisms
(Table 2).4,12,16 Piperacillin-tazobactam and carbapenems
may be more reliable antibiotics for empiric treatment of
hospital-acquired bacteremia caused by B. vesicularis.
Although no resistance to trimethoprim/sulfamethoxazole
has been reported, there is no therapeutic experience with
this regimen.
Our report is limited by the lack of quantitative data.
The minimum inhibitory concentration and minimum
bactericidal concentration were not determined. It is
difficult to choose the best antimicrobial agent for the
treatment of invasive B. vesicularis infections without
these data. Eight of the previously reported cases were
successfully treated with a second- or third-generation
cephalosporin with or without an aminoglyco-
side4,5,7,10,11,15; three cases were treated with a b-lactam/
b-lactamase inhibitor6,8,16 and three cases were treated
with ciprofloxacin alone or combined with an aminoglyco-
side or a monobactam12e14 (Table 1).
Laboratory identification of B. vesicularis is based on
colony morphology in blood agar plate, Gram stain and
biochemistry test. The 16S rRNA sequencing method is
a robust alternative method for the rapid identification of
pathogens, especially those that are rare or difficult
to identify by conventional methods. B. vesicularis was
rapidly confirmed with 16S rRNA sequencing method
compared with the GenBank reference number, as the
previous method. Lee et al reported that 30 patients had
Brevundimonas species bacteremia confirmed using the 16S
rRNA sequencing method, which was more specific than
commercial methods of Phoenix and the Vitek 2 system.17
More experience will be necessary to establish the
minimum inhibitory concentration and minimum bactericidal
Table 1 Clinical features in past English literature reporting Brevundimonas vesicularis infection
No. Age Sex Underlying condition(s) Clinical presentationa Source of
culture
Treatment/durationb Outcome Author, year
1 67Y M hemodialysis, reused dialyzers bacteremia/HA blood CTX þ TOB/unknown recovered Vanholder R, 1990 & 1992
2 62Y F hemodialysis, reused dialyzers bacteremia/HA blood CTX þ TOB/unknown recovered Vanholder R, 1990 & 1992
3 54Y F systemic lupus erythematosus,
autoimmune hepatitis, steroid
therapy
bacteremia/HA blood CTZ þ TOB/15 d;
debridement; skin
autograft
recovered Planes AM, 1992
4 5Y M sickle cell anemia pneumonia/CA blood CRO/1 d; CRO þ GM/10 d recovered Oberhelman RA, 1994
5 60Y M trauma botryomycosis/CA soft tissue CXM/4 mo recovered Calegari L, 1996
6 42Y F mitral valve replacement bacteremia/HA blood PIP-TZ/14 d recovered Gilad J, 2000
7 38Y M no tonsillitis/CA blood AM-CL/3 d recovered Chi CY, 2004
8 37Y F acute myeloid leukemia,
pregnancy, pancytopenia
necrotizing cellulitis;
bacteremia/HA
blood PIP-TZ þ CC/unknown recovered Niedermeier DM, 2005
9 24Y M pilocytic astrocytoma meningitis/HA cerebral
spinal fluid
CRO/not reported;
CIP þ AN/15 d
recovered Mondello P, 2006
10 40Y M abscess of molar cavity infective endocarditis/CA blood CZ þ GM/3 d;
AM-SB þ GM/5 d;
CRO þ GM/7 d; CIP/30 d
recovered Yang ML, 2006
11 55Y M diabetes, continuous
ambulatory peritoneal dialysis
peritonitis/CA peritoneal
fluid
CZ þ CTZ/3 d;
Vanco þ CTZ/4 d;
CIP þ AZN/14 d
recovered Choi W, 2006
12 15 M F young age septic arthritis/CA synovial fluid CXM/12 d; cephalexin/
14 d
recovered Sofer Y, 2007
13 71Y M trauma, exposed to farm
animals
cutaneous infection/CA soft tissue cefpodoxime/7 d;
AM-CL/14 d
recovered Panasiti V, 2008
14 83Y M coronary artery bypass grafting bacteremia/HA blood CTZ/14 d recovered present case 1
15 25Y M anaplastic large T-cell
lymphoma, neutropenia
bacteremia/HA blood VA þ FEP/5 d; CRO/10 d recovered present case 2
a CAZ community-acquired infection; HAZ hospital-acquired infection. Hospital-acquired infections are those that originate in a hospital or hospital-like settings, if they first appear
48 hours or more after admission.
b AM-CLZ amoxicillin/clavulanate; AM-SBZ ampicillin/sulbactam; ANZ amikacin; AZNZ aztreonam; CCZ clindamycin; CIPZ ciprofloxacin; CROZ ceftriaxone; CTXZ cefotaxime;
CTZ Z ceftazidime; CXM Z cefuroxime; CZ Z cefazolin; GM Z gentamicin; TOB Z tobramycin; PIP-TZ Z piperacillin/tazobactam; Vanco Z vancomycin.
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Table 2 In vitro drug susceptibility in reported cases of Brevundimonas vesicularis
Patient numbera 3 4 6 7 9 10 11 12 13 case 1 case 2
Year 1992 1994 2000 2004 2006 2006 2006 2007 2008 2009 2009
Antibioticsb HA CA HA CA HA CA CA CA CA HA HA
Ampicillin S d R R d S d S d R R
AM-CL d d S d d d d S S d d
AM-SB d d d d d d d d d S S
Piperacillin R S S d R S S d d d d
PIP-TZ d d S S d d d d d S S
Cefazolin S d d R R S d S d S S
Cefuroxime d d R S d d d S R d d
Cefoxitin S d d d d d d S R d d
Cefotaxime S d d S d S d S d d d
Ceftriaxone d S R S d S d S d S S
Ceftazidime R S R R d S S S R S R
Cefepime d d d d d S S d S S R
Gentamicin S S S R R S S S R S S
Tobramycin S d S R d d d S R d d
Amikacin S d S S R S d S R S S
Imipenem d d S S R d S d d S S
Meropenem d d d d R S d d d d d
Ertapenam d d d d d d d d d S S
Aztreonam d d R R R S S d d d d
Ciprofloxacin d S R R S S S S S R R
TMP-SXT S d S S S S S S d d d
AM-CLZamoxicillin/clavulanate; AM-SBZampicillin/sulbactam;CAZ community-acquired infection; HAZhospital-acquired infection;
PIP-TZZ piperacillin/tazobactam; RZ resistant; SZ susceptible; TMP-SXTZ trimethoprim/sulfamethoxazole;dZ not determined.
a There were no available results of susceptibility tests in patients 1, 2, 5 and 8, as presented in Table 1.
b The susceptibility tests of the isolates in the reported cases and the present cases were determined by various methods, such as disc
diffusion method, automatic micro-diffusion, etc.
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choice of antibiotic therapy for B. vesicularis infections.
Although thought to be an opportunistic pathogen in clin-
ical practice, B. vesicularis may also be the cause of
hospital-acquired bacteremia. Of the 22 patients with B.
vesicularis bacteremia reported by Lee et al, infection was
predominant in males (70%) and in those with underlying
malignancies (55%). All community-acquired and nosoco-
mial strains were 100% susceptible to piperacillin/
tazobactam and amikacin. The mortality rate at 14 days
was 14%.17
Empiric therapy with one antibiotic, which is used for
hospital-acquired glucose nonfermenting GNB infections,
seems to be unsuitable for hospital-acquired B. vesicularis
infections. Although good outcomes have been reported in
B. vesicularis infections, initial empiric therapy with anti-
pseudomonal antibiotics plus trimethoprim/sulfamethox-
azole for hospital-acquired B. vesicularis infections might
be considered before completing the susceptibility tests.
The optimal therapeutic duration for B. vesicularis infec-
tions in various situations remains to be established.
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